線上 必修 錄影回放 三合一氣喘吸入劑(講師:林慶雄)-2

時間 2025/08/31
費用 非會員 900元 ; 會員 300元 ;
名額 非會員 99位 (剩餘名額:99)
會員 99位 (剩餘名額:82)
學分 依規定全程參與(簽到及簽退)課程者將給2學分
課程內容
  • 課程主題:三合一氣喘吸入劑
  • 課程講師:林慶雄  講師
  • 錄製日期:2024.5.5
  • 操作方式:點選本頁報名,繳費後至線上課程觀看
  • 學分認定:觀看完整影片後(須完成進度100%)即認學分
  • 其他說明:聲音較小,請自行調整放大音量
  • 課程講義:報名後至附件下載
  • 摘要:Triple inhaler therapy, which includes the combination of inhaled corticosteroids (ICS), long-acting β2-agonists (LABA), and long-acting muscarinic antagonists (LAMA), has shown promising results in the treatment of uncontrolled asthma. Studies have demonstrated that triple therapy, whether delivered through a single inhaler or separate inhalers, can lead to a reduction in asthma symptoms, exacerbations, and hospitalizations. Additionally, triple therapy has been associated with improvements in lung function, asthma control, and health-related quality of life. In real-world settings, extrafine single-inhaler triple therapy (efSITT) has shown clinical benefits in patients with asthma not adequately controlled on LABA and medium- or high-dose ICS. Furthermore, first-line triple therapy has been found to be effective in managing controller-naïve and symptomatic adult patients with asthma, leading to improved disease control. Overall, triple inhaler therapy appears to be a valuable treatment option for patients with uncontrolled asthma, offering improved outcomes and potentially reducing the need for dose escalation or alternative treatments.
附件

我要報名